Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (221-230 of 232) with videos related to

Pageof 24
Sort By:
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
JCO Oncology Practice|March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Leukemia|May 11, 2019
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR studyCelalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
The British Journal of Ophthalmology|September 16, 2022
Risk factors associated with abandonment of care in retinoblastoma: analysis of 692 patients from 10 countriesThamanna Nishath, Xiudi Li, Arthika Chandramohan, et al.
Pageof 24

Showing results (221-230 of 232) with videos related to

Sort By:
Pageof 24
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
JCO Oncology Practice|March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Leukemia|May 11, 2019
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR studyCelalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
The British Journal of Ophthalmology|September 16, 2022
Risk factors associated with abandonment of care in retinoblastoma: analysis of 692 patients from 10 countriesThamanna Nishath, Xiudi Li, Arthika Chandramohan, et al.
Pageof 24